• Part A: No gender limitation. Patients with histologically and/or cytologically confirmed ALK/ROS1 gene fusion positive non-small cell lung cancer and various advanced tumors.

• Part B: Female only. Histologically proven ovarian epithelial, fallopian tube, or primary peritoneal carcinoma.

• At least one measurable tumor lesion.

• ECOG score is 0\

• Life expectancy of ≥3 months.

• AE caused by previous treatment must recover to ≤ grade 1.

• Sufficient bone marrow, liver, kidney and coagulation function.

• Female patients must be in a non-pregnant and non-lactating state.

• Able to understand and willing to sign informed consent.

• Patients are required to provide fresh or archived tumor tissue samples prior to treatment.